[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201892369A1 - Способы селективной модуляции активности отдельных подтипов клеток - Google Patents

Способы селективной модуляции активности отдельных подтипов клеток

Info

Publication number
EA201892369A1
EA201892369A1 EA201892369A EA201892369A EA201892369A1 EA 201892369 A1 EA201892369 A1 EA 201892369A1 EA 201892369 A EA201892369 A EA 201892369A EA 201892369 A EA201892369 A EA 201892369A EA 201892369 A1 EA201892369 A1 EA 201892369A1
Authority
EA
Eurasian Patent Office
Prior art keywords
activity
particles
subtips
methods
retroviral vectors
Prior art date
Application number
EA201892369A
Other languages
English (en)
Inventor
Каролин Коста Фехос
Эльс Верхёйен
Франсуа-Лоик Коссе
Рубен Бендер
Кристиан Бухгольц
Ци Чжоу
Original Assignee
Эколь Нормаль Сюпериёр Де Лион
Сентр Насьональ Де Ля Решерш Сьентифик
Юниверсите Клод Бернар Лион I
Институт Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль (Инсерм)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эколь Нормаль Сюпериёр Де Лион, Сентр Насьональ Де Ля Решерш Сьентифик, Юниверсите Клод Бернар Лион I, Институт Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль (Инсерм) filed Critical Эколь Нормаль Сюпериёр Де Лион
Publication of EA201892369A1 publication Critical patent/EA201892369A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31Chimeric antigen receptors [CAR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4202Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203Receptors for growth factors
    • A61K40/4205Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4202Receptors, cell surface antigens or cell surface determinants
    • A61K40/421Immunoglobulin superfamily
    • A61K40/4211CD19 or B4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4237Hormones, e.g. calcitonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5418IL-7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57Skin; melanoma
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045Special targeting system for viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18211Henipavirus, e.g. hendra virus
    • C12N2760/18222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18411Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18411Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)

Abstract

Настоящее изобретение относится к псевдотипированным ретровирусоподобным частицам или ретровирусным векторам, содержащим и сконструированные гликопротеины оболочки, происходящие из вируса семейства Paramyxoviridae, слитые с доменом, нацеливающим на клетку, и слитые с функциональным доменом. Настоящее изобретение также относится к применению указанных псевдотипированных ретровирусоподобных частиц или ретровирусных векторов для селективной модуляции активности специфических поднаборов клеток, в частности специфических иммунных клеток. Данные псевдотипированные ретровирусоподобные частицы или ретровирусные векторы являются особенно полезными для генотерапии, иммунотерапии и/или вакцинации.
EA201892369A 2016-04-21 2017-04-20 Способы селективной модуляции активности отдельных подтипов клеток EA201892369A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305468.7A EP3235908A1 (en) 2016-04-21 2016-04-21 Methods for selectively modulating the activity of distinct subtypes of cells
PCT/EP2017/059435 WO2017182585A1 (en) 2016-04-21 2017-04-20 Methods for selectively modulating the activity of distinct subtypes of cells

Publications (1)

Publication Number Publication Date
EA201892369A1 true EA201892369A1 (ru) 2019-05-31

Family

ID=56008561

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892369A EA201892369A1 (ru) 2016-04-21 2017-04-20 Способы селективной модуляции активности отдельных подтипов клеток

Country Status (15)

Country Link
US (2) US11608509B2 (ru)
EP (3) EP3235908A1 (ru)
JP (4) JP7412885B2 (ru)
KR (1) KR20190046713A (ru)
CN (2) CN117126817A (ru)
AU (3) AU2017253364B2 (ru)
BR (1) BR112018071584A2 (ru)
CA (1) CA3021549A1 (ru)
EA (1) EA201892369A1 (ru)
ES (1) ES2961976T3 (ru)
IL (1) IL262458A (ru)
MX (2) MX2018012814A (ru)
SG (1) SG11201809164TA (ru)
WO (1) WO2017182585A1 (ru)
ZA (1) ZA201807161B (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
US11576872B2 (en) 2017-05-08 2023-02-14 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
IL278665B2 (en) * 2018-05-15 2024-10-01 Flagship Pioneering Innovations V Inc Fusosome compositions and uses thereof
AU2019301053A1 (en) * 2018-07-09 2021-01-28 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
US20230043255A1 (en) * 2018-11-14 2023-02-09 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
CN110004181B (zh) * 2019-03-20 2022-10-11 东北农业大学 一种附加型CRISPR/Cas9表达载体及其构建方法与应用
JP2022534085A (ja) 2019-05-23 2022-07-27 マサチューセッツ インスティテュート オブ テクノロジー リガンドの発見およびレトロウイルス表面ディスプレーを介した遺伝子送達
CA3152525A1 (en) 2019-09-03 2021-03-11 Sana Biotechnology, Inc. Cd24-associated particles and related methods and uses thereof
CN110904116B (zh) * 2019-10-24 2022-12-09 中国科学院遗传与发育生物学研究所 植物phl3基因在调控植物种子大小、干重和脂肪酸积累中的应用
AU2021236226A1 (en) * 2020-03-11 2022-09-15 The Trustees Of The University Of Pennsylvania Methods and composition for gene delivery using an engineered viral particle
US20210353543A1 (en) * 2020-03-31 2021-11-18 Sana Biotechnology, Inc. Targeted lipid particles and compositions and uses thereof
WO2022013872A1 (en) * 2020-07-14 2022-01-20 Ichilov Tech Ltd. Pseudotyped viruses configured to express car in t-cells
EP3964585A1 (en) * 2020-09-03 2022-03-09 Miltenyi Biotec B.V. & Co. KG Cd62l specific lentiviral vector particle for targeted transduction of t cell subsets
MX2023008081A (es) * 2021-01-11 2023-09-12 Sana Biotechnology Inc Uso de vectores virales dirigidos a cd8.
WO2022187289A1 (en) 2021-03-01 2022-09-09 Exuma Biotech Corp. Methods and compositions for the delivery of retroviral particles
JP2024532963A (ja) 2021-04-08 2024-09-11 サナ バイオテクノロジー,インコーポレイテッド Cd8特異的抗体コンストラクト及びその組成物
IL308836A (en) 2021-05-28 2024-01-01 Sana Biotechnology Inc Lipid Particles Containing Baboon Truncated Endogenous Retrovirus (BAEV) Envelope Glycoprotein and Related Methods and Uses
WO2023015217A1 (en) 2021-08-04 2023-02-09 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023114698A2 (en) * 2021-12-13 2023-06-22 Interius Biotherapeutics, Inc. Engineered viral particles and uses of the same
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
EP4448775A1 (en) 2021-12-17 2024-10-23 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
EP4448549A2 (en) 2021-12-17 2024-10-23 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023168305A1 (en) 2022-03-01 2023-09-07 Exuma Biotech Corp. Viral particles with membrane-bound hyaluronidase
EP4493157A2 (en) * 2022-03-11 2025-01-22 President and Fellows of Harvard College Targeted delivery of armms
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023210616A1 (ja) * 2022-04-25 2023-11-02 ときわバイオ株式会社 Rnaウイルス由来のキメラエンベロープタンパク質及び該タンパク質を持つrnaウイルスベクター
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220598A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Lentiviral vectors with two or more genomes
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
WO2024243340A1 (en) 2023-05-23 2024-11-28 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2024254346A1 (en) * 2023-06-07 2024-12-12 The Broad Institute, Inc. Engineered viral like particles (evlps) for the selective transduction of target cells
CN117659133B (zh) * 2023-12-06 2024-09-20 南京鼓楼医院 间皮素靶向结合蛋白、其编码核酸以及用途
CN118108809A (zh) * 2024-03-15 2024-05-31 西湖实验室(生命科学和生物医学浙江省实验室) 一种跨膜荧光蛋白、水溶荧光蛋白及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6328999A (en) 1998-09-23 2000-04-10 Institut Fur Virologie Teilrechtsfahiges Institut An Der Veterinarmedizinischen Universitat Wien Retroviral particles protected against complement mediated destruction
US6896881B1 (en) * 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
US20020150556A1 (en) 2000-03-31 2002-10-17 Vile Richard G. Compositions and methods for tissue specific gene regulation therapy
EP1469730A4 (en) 2001-10-30 2006-02-01 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE
US6790641B2 (en) 2002-05-01 2004-09-14 Cell Genesys, Inc. Lentiviral vector particles resistant to complement inactivation
US20060045910A1 (en) 2004-09-02 2006-03-02 Ehringer William D Preserved fusogenic vesicles
GB0426641D0 (en) 2004-12-03 2005-01-05 Bioactive Protein Delivery The Protein delivery system
CN101065488A (zh) 2005-01-20 2007-10-31 新加坡科技研究局 将核酸递送到外周神经元的方法
WO2006115843A2 (en) 2005-04-25 2006-11-02 Merial Limited Nipah virus vaccines
WO2007005244A1 (en) 2005-07-05 2007-01-11 The Regents Of The University Of California Henipavirus receptor and uses thereof
WO2008115199A2 (en) 2006-08-18 2008-09-25 The University Of North Carolina At Chapel Hill Chimeric virus vaccines
EP1975239A1 (en) * 2006-09-27 2008-10-01 Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening
WO2008071959A1 (en) 2006-12-12 2008-06-19 Oxford Biomedica (Uk) Limited Lentiviral vectors comprising micrornas
ES2746907T5 (es) 2008-04-22 2024-12-11 Vib Vzw Elementos reguladores de ácido nucleico específicos de hígado y métodos y uso de los mismos
US20120020878A1 (en) 2008-11-07 2012-01-26 Children's Hospital Medical Center Fusogenic properties of saposin c and related proteins and peptides for application to transmembrane drug delivery systems
HUE043032T2 (hu) 2009-07-24 2019-07-29 Immune Design Corp Nem-integrálódó lentivírus vektorok
WO2011058052A1 (en) 2009-11-13 2011-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Direct protein delivery with engineered microvesicles
EP2476754A1 (en) 2011-01-14 2012-07-18 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
EP2701686A4 (en) 2011-04-28 2014-11-05 Stc Unm LIPID BINCHES SUPPORTED ON POROUS NANOPARTICLES (PROTOCELLS) FOR TARGETED ADMINISTRATION, AND METHODS OF USE THEREOF
BR112014008932A2 (pt) * 2011-10-14 2019-09-24 Sandia Corp bicamadas lipídicas suportadas em nanopartículas porosas (protocélulas) para administração direcionada, incluindo a administração transdérmica de uma carga e métodos associados
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
EP2615176A1 (en) * 2012-01-11 2013-07-17 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Novel pseudotyped lentiviral particles and their use in the in vitro targeted transduction of undifferentiated pluripotent human embryonic stem cells and induced pluripotent stem cells
US9486539B2 (en) 2012-03-26 2016-11-08 The Regents Of The University Of California Nipah virus envelope pseudotyped lentiviruses and methods of their use
ES2686129T3 (es) 2012-11-13 2018-10-16 Codiak Biosciences, Inc. Administración de agentes terapéuticos
KR102353885B1 (ko) 2013-03-13 2022-01-20 이미지냅 인코포레이티드 Cd8에의 항원 결합 구조체들
GB201313249D0 (en) 2013-07-25 2013-09-11 Isis Innovation Method
KR102507475B1 (ko) 2014-01-21 2023-03-07 안자리움 바이오사이언시스 아게 하이브리도좀, 이를 포함하는 조성물, 이의 제조 방법 및 이의 용도
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
US10421979B2 (en) * 2015-02-11 2019-09-24 Alma Mater Studiorum Universita' Di Bologna Retargeted herpesvirus with a glycoprotein H fusion
WO2016138525A1 (en) 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
US20180135012A1 (en) 2015-05-13 2018-05-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
WO2017151717A1 (en) 2016-03-01 2017-09-08 French Brent A Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells
MX2018011345A (es) * 2016-03-19 2019-05-27 F1 Oncology Inc Métodos y composiciones para transducir linfocitos y expansión regulada de los mismos.
WO2018009923A1 (en) 2016-07-08 2018-01-11 F1 Oncology, Inc. Methods and compositions for transducing lymphocytes and regulating the activity thereof
WO2017173034A1 (en) 2016-03-30 2017-10-05 The University Of North Carolina At Chapel Hill Biological agent-exosome compositions and uses thereof
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
AU2017276727B2 (en) 2016-06-09 2023-10-05 Alma Mater Studiorum Universita Di Bologna Herpesvirus with modified glycoprotein H for propagation in a cell
CN110073000A (zh) 2016-07-26 2019-07-30 森迪生物科学公司 遗传擦除子
CN110678208B (zh) 2017-01-09 2024-04-05 奥依信生物技术公司 膜融合脂质纳米颗粒和制造方法以及用于产生治疗性蛋白质和用于治疗的用途
US11576872B2 (en) 2017-05-08 2023-02-14 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
US20210187018A1 (en) 2017-12-07 2021-06-24 Flagship Pioneering Innovations V, Inc. Cytobiologics and therapeutic uses thereof
JP2021512126A (ja) 2018-02-01 2021-05-13 バイオベラティブ セラピューティクス インコーポレイテッド 第viii因子を発現するレンチウイルスベクターの使用
WO2019161281A1 (en) 2018-02-17 2019-08-22 Flagship Pioneering Innovations V, Inc. Compositions and methods for membrane protein delivery
IL278665B2 (en) 2018-05-15 2024-10-01 Flagship Pioneering Innovations V Inc Fusosome compositions and uses thereof
US20210198698A1 (en) 2018-07-09 2021-07-01 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
AU2019301053A1 (en) 2018-07-09 2021-01-28 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
SG11202105079QA (en) 2018-11-14 2021-06-29 Flagship Pioneering Innovations V Inc Fusosome compositions for cns delivery
US20230043255A1 (en) 2018-11-14 2023-02-09 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
US20230048166A1 (en) 2018-11-14 2023-02-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
SG11202105085QA (en) 2018-11-14 2021-06-29 Flagship Pioneering Innovations V Inc Compositions and methods for compartment-specific cargo delivery

Also Published As

Publication number Publication date
JP2019514373A (ja) 2019-06-06
AU2023258359A1 (en) 2024-01-18
AU2017253364B2 (en) 2020-07-02
US20230348934A1 (en) 2023-11-02
IL262458A (en) 2018-12-31
ES2961976T3 (es) 2024-03-14
JP7577039B2 (ja) 2024-11-01
KR20190046713A (ko) 2019-05-07
EP3445862A1 (en) 2019-02-27
AU2017253364A1 (en) 2018-11-15
US20190144885A1 (en) 2019-05-16
US11608509B2 (en) 2023-03-21
MX2023006961A (es) 2023-06-23
JP2022087199A (ja) 2022-06-09
EP3445862B1 (en) 2023-10-25
WO2017182585A1 (en) 2017-10-26
CA3021549A1 (en) 2017-10-26
EP4151737A1 (en) 2023-03-22
NZ747658A (en) 2024-04-26
ZA201807161B (en) 2019-06-26
MX2018012814A (es) 2019-06-20
BR112018071584A2 (pt) 2019-03-12
JP7412885B2 (ja) 2024-01-15
JP2024028379A (ja) 2024-03-04
SG11201809164TA (en) 2018-11-29
CN109642243A (zh) 2019-04-16
EP4151737A8 (en) 2023-12-20
JP2021184767A (ja) 2021-12-09
EP3235908A1 (en) 2017-10-25
AU2020203813B2 (en) 2023-08-03
CN117126817A (zh) 2023-11-28
AU2020203813A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
EA201892369A1 (ru) Способы селективной модуляции активности отдельных подтипов клеток
PH12019501130A1 (en) Viral delivery of neoantigens
MX2022006652A (es) Proteinas de capside modificadas para un suministro mejorado de vectores de parvovirus.
EA201692361A1 (ru) Лентивирусные векторы
GB2573664A (en) Viral methods of T cell therapy
PH12017501942A1 (en) Oncolytic adenovirus encoding a b7 protein
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
MY194289A (en) Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, and Methods of use
NZ735344A (en) Methods and compositions for treating genetic eye diseases
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
EA201790534A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для генной терапии
EA201491813A1 (ru) Лентивирусные векторные частицы, имеющие улучшенную эффективность трансдукции клеток, экспрессирующих dc-sign
EP2550359A4 (en) VECTORS FOR THE CONDITIONAL EXPRESSION OF THERAPEUTIC PROTEINS, HOST CELLS WITH THESE VECTORS, AND USES THEREOF
EA201490627A1 (ru) Соединения для улучшенной вирусной трансдукции
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
PH12016502554A1 (en) A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection
CR20210370A (es) Neoantígenos prostáticos y sus usos
EA202090700A1 (ru) Компетентные по репликации аденовирусные векторы
EP3998341A3 (en) Adenoviral vectors
EA201890351A1 (ru) Рекомбинантный orf-вирусный вектор
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
EA202090628A1 (ru) Система экспрессии paramyxoviridae
EA201992558A1 (ru) Варианты белка bmp7 человека
EA201791442A1 (ru) Способы лечения гематологических нарушений, солидных опухолей или инфекционных заболеваний с применением естественных клеток-киллеров
EA202191919A1 (ru) Неоантигены предстательной железы и их применение